These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
285 related articles for article (PubMed ID: 16509071)
1. [IgA nephropathy: from predicting progression to treatment]. Rauta V; Grönhagen-Riska C Duodecim; 2006; 122(2):215-22. PubMed ID: 16509071 [No Abstract] [Full Text] [Related]
2. Prognostic factors and therapy assessment of IgA nephropathy: report from a single unit in iran. Soleymanian T; Najafi I; Salimi BH; Broomand B Ren Fail; 2011; 33(6):572-7. PubMed ID: 21663387 [TBL] [Abstract][Full Text] [Related]
3. Modulating the progression in IgA nephropathy. Chan JC; Trachtman H Nephron Clin Pract; 2006; 104(1):c61-8. PubMed ID: 16741372 [TBL] [Abstract][Full Text] [Related]
4. [Diagnosis of and therapy for IgA nephropathy]. Tomino Y Nihon Naika Gakkai Zasshi; 2004 Mar; 93(3):483-7. PubMed ID: 15052807 [No Abstract] [Full Text] [Related]
10. [IgA nephropathy (immunoglobulin A nephropathy, M.Berger). Main symptoms: (painless) macrohematuria or microhematuria]. Kolyvanos Naumann U; Käser L; Vetter W Praxis (Bern 1994); 2004 Oct; 93(44):1809-13; quiz 1814. PubMed ID: 15559904 [No Abstract] [Full Text] [Related]
11. Sjogren's syndrome complicated with IgA nephropathy and leukocytoclastic vasculitis. Tsai TC; Chen CY; Lin WT; Lee WJ; Chen HC Ren Fail; 2008; 30(7):755-8. PubMed ID: 18704825 [TBL] [Abstract][Full Text] [Related]
12. Reply to Yang et al. Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin receptor blocker (ARB) in pediatric patients with IgA nephropathy. Mandal A Clin Nephrol; 2006 Mar; 65(3):227; author reply 227-8. PubMed ID: 16550756 [No Abstract] [Full Text] [Related]
13. Progression of chronic kidney disease: can it be prevented or arrested? Malani AK; Ammar H; Yassin MH Am J Med; 2007 Mar; 120(3):e29; author reply e31. PubMed ID: 17349429 [No Abstract] [Full Text] [Related]
14. The rationale and indications for angiotensin receptor blockers in heart failure. Bybee KA; Das S; O'Keefe JH Heart Fail Clin; 2006 Jan; 2(1):81-8. PubMed ID: 17386879 [No Abstract] [Full Text] [Related]
16. Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy. Nakamura T; Inoue T; Sugaya T; Kawagoe Y; Suzuki T; Ueda Y; Koide H; Node K Am J Hypertens; 2007 Nov; 20(11):1195-201. PubMed ID: 17954367 [TBL] [Abstract][Full Text] [Related]
17. Treatment of IgA nephropathy. Pozzi C J Nephrol; 2016 Feb; 29(1):21-5. PubMed ID: 26577268 [TBL] [Abstract][Full Text] [Related]
18. [Therapeutic effects of RAS inhibitor in IgA nephropathy]. Kashihara N Nihon Jinzo Gakkai Shi; 2008; 50(4):473-7. PubMed ID: 18546877 [No Abstract] [Full Text] [Related]
19. The effects of angiotensin-converting enzyme gene polymorphism on the progression of immunoglobulin A nephropathy in Malaysian patients. Draman CR; Kong NC; Gafor AH; Rahman AF; Zainuddin S; Mustaffa WM; Radzi AM; Shamsul AS Singapore Med J; 2008 Nov; 49(11):924-9. PubMed ID: 19037561 [TBL] [Abstract][Full Text] [Related]
20. Quantitative appraisal of treatment options for IgA nephropathy. Ballardie FW J Am Soc Nephrol; 2007 Nov; 18(11):2806-9. PubMed ID: 17942959 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]